We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Nicox: Second notice of the Ordinary and Extraordinary Shareholders' Meeting on May 6, 2024 and appointment of an ad hoc agent Press Release Nicox: Second notice of the Ordinary and...
Nicox Provides First Quarter 2024 Update and Full Year 2023 Financial Results Press Release Nicox Provides First Quarter 2024 Update and Full Year 2023 Financial Results Nicox Group revenue...
Nicox: 2024 Ordinary and Extraordinary Shareholder Meeting Press Release Nicox: 2024 Ordinary and Extraordinary Shareholder MeetingApril 9, 2024 – release at 17:30 CET Sophia Antipolis...
Nombre de droits de vote au 31 mars 2024 Nicox SA Société anonyme au capital de 50 299 694 euros Siège social : Sundesk Sophia Antipolis, Emerald Square, rue Evariste Galois, 06410...
Nicox - Lettre aux Actionnaires Madame, Monsieur, Cher Actionnaire, L’Assemblée générale ordinaire et extraordinaire convoquée pour le 10 avril prochain est d’une importance particulière pour...
Nicox : Publication de résultats de l’étude de phase 3 Mont Blanc sur le NCX 470 dans le glaucome dans la revue American Journal of Ophthalmology Communiqué de presse Nicox : Publication de...
Results from Mont Blanc Phase 3 Trial of Nicox’s NCX 470 in Glaucoma Published in the American Journal of Ophthalmology Press Release Results from Mont Blanc Phase 3 Trial of Nicox’s NCX 470 in...
Nicox Updates on Corporate, Pipeline and Financing Perspectives and Will Hold a Webcast on March 18, 2024 Press Release Nicox Updates on Corporate, Pipeline and Financing Perspectives and Will...
Nicox fait le point sur les perspectives de son développement, de son portefeuille de produits et de son financement et tiendra une réunion par webcast le 18 mars 2024 Communiqué de presse Nicox...
Nicox Announces Presentation of Data on NCX 470 at the 2024 American Glaucoma Society Annual Meeting Press Release Nicox Announces Presentation of Data on NCX 470 at the 2024 American Glaucoma...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
12 | 0 | 0 | 5.67 | 5.67 | 5.67 | 25 | 5.67 | DE |
26 | 0 | 0 | 5.67 | 5.67 | 5.67 | 2913 | 5.67 | DE |
52 | 0 | 0 | 5.67 | 5.67 | 5.67 | 2917 | 5.67 | DE |
156 | 0 | 0 | 5.67 | 5.67 | 5.67 | 4047 | 5.67 | DE |
260 | 0 | 0 | 5.67 | 5.67 | 5.67 | 4403 | 5.67 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions